Processa Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0.0 | $0.0 |
| Operating income | -$14.0 | -$12.1 | -$11.5 | -$27.5 | -$12.1 |
| Net income | -$13.6 | -$11.9 | -$11.1 | -$27.4 | -$11.4 |
| Cash Flow Statement | |||||
| Free cash flow | — | -$11.2 | -$8.1 | — | — |
| Share repurchases | — | — | — | $0.3 | — |
Shares outstanding 2.8M · Free float 25.2%
Annual filing data through FY ended December 31, 2025; float as of September 11, 2026.